Thursday, 19 Sep 2019

You are here

Health Canada Issues Acetaminophen Advisory

Yesterday Health Canada announced it “is taking additional steps to minimize the risk of liver damage and improve acetaminophen safety,” citing the findings of a government review that underscored the possibility of accidental overdose.

Of the 4 billion doses of acetaminophen sold in Canada each year, there were 4000 hospitalizations for acetaminophen overdose - 20% of these were using doses in excess of 4000 mg per day. A Statistics Canada database recorded 253 accidental deaths and nearly 300 suicides between 2000 and 2009 where acetaminophen was a major or contributing cause of death.

Acetaminophen By the Numbers

4 billion — Number of doses of acetaminophen sold in Canada each year

475 — The number of different acetaminophen products currently authorized for marketing in Canada

4 — Number of grams of acetaminophen in the recommendation maximum daily dose

10 — Number of grams of acetaminophen per day that can lead to liver damage

4,000 — Number of hospitalizations in Canada each year for acetaminophen overdose

20 — Percentage of hospitalizations for acetaminophen overdose due to people exceeding the recommended dose unintentionally

250 — Number of cases of serious liver injury per year in Canada related to acetaminophen

50 — Percentage of cases of serious liver injury associated with unintentional overdoses

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.